4-Ethenyl-3,5-dimethyl-1-phenylpyrazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-Ethenyl-3,5-dimethyl-1-phenylpyrazole
• 化学式: C₁₃H₁₄N₂
• 分子量: 198.26
• InChiKey: ILDQEQZYQPNHLX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-phenyl-3,5-dimethyl-4-(2-chloroethyl)pyrazole 、 氢氧化钾 以40%的产率得到
  参考文献：
  名称：

  ISMAILOV, V. A.;BAJRAMOV, M. R.;SADYXOV, N. S.;GUSEJNOVA, R. A., AZERB. XIM. ZH.,(1988) N, S. 73-77

  摘要：

  DOI：

文献信息

• ADENOSINE A2A RECEPTOR ANTAGONISTS
  申请人：Moorman Allan R.

  公开号：US20080242672A1

  公开（公告）日：2008-10-02

  The present invention provides compounds of the formula wherein R 1 and R 2 have meaning as defined herein in the specification. The compounds of formula (I) are adenosine A 2A receptor antagonists and, thus, may be employed for the treatment of conditions and diseases mediated by the adenosine A 2A receptor activity. Such conditions include, but are not limited to, diseases of the central nervous system such as depression, cognitive function diseases and neurodegenerative diseases such as Parkinson's disease, senile dementia as in Alzheimer's disease or psychoses and stroke. The compounds of the present invention may also be employed for the treatment of attention related disorders such as attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD), extra pyramidal syndrome, e.g., dystonia, akathisia, pseudoparkinsonism and tardive dyskinesia, and disorders of abnormal movement such as restless leg syndrome (RLS) and periodic limb movement in sleep (PLMS); cirrhosis, and fibrosis and fatty liver; dermal fibrosis in diseases such as scleroderma; and the mitigation of addictive behavior. In particular, the compounds of the present invention may be employed to improve motor-impairment due to neurodegenerative diseases such as Parkinson's disease.

  本发明提供了以下式的化合物 其中R 1 和R 2 的含义如规范中所定义。式(I)的化合物是腺苷A 2A 受体拮抗剂，因此可用于治疗由腺苷A 2A 受体活性介导的疾病和病症。这些疾病包括但不限于中枢神经系统疾病，如抑郁症、认知功能疾病和神经退行性疾病，如帕金森病、老年性痴呆症、精神病和中风。本发明的化合物还可用于治疗注意力相关障碍，如注意力缺陷障碍（ADD）和注意力缺陷多动障碍（ADHD），额外锥体综合征，例如肌张力障碍、不安坐立、假性帕金森症和迟发性运动障碍，以及异常运动障碍，如不宁腿综合征（RLS）和睡眠中期肢体运动（PLMS）；肝硬化、纤维化和脂肪肝；在硬皮病等疾病中的皮肤纤维化；以及对成瘾行为的缓解。特别是，本发明的化合物可用于改善由帕金森病等神经退行性疾病引起的运动障碍。
• Novel piperidine derivative
  申请人：Ban Hitoshi

  公开号：US20070078120A1

  公开（公告）日：2007-04-05

  The invention provides a compound of the following formula (1): wherein m, n, and p are independently an integer of 0-4, provided 3≦m+n≦8; X is nitrogen atom or a group of the formula: C—R 15 ; Y is a substituted or unsubstituted aromatic group, etc.; R 15 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are hydrogen atom, a substituted or unsubstituted alkyl group, etc.; and Z is hydrogen atom, cyano group, etc., or a prodrug thereof, or a pharmaceutically acceptable salt thereof, which exhibits an action for enhancing LDL receptor expression, and is useful as a medicament for treating hyperlipidemia, atherosclerosis, etc.

  本发明提供了以下式(1)的化合物：其中m，n和p分别是0-4的整数，满足3≦m+n≦8；X是氮原子或式：C—R15的基团；Y是取代或未取代的芳香基团等；R15，R1，R2，R3，R4，R5，R6和R7是氢原子，取代或未取代的烷基等；Z是氢原子，氰基等，或其前药，或其药学上可接受的盐，具有增强LDL受体表达的作用，并且可用作治疗高脂血症，动脉粥样硬化等药物。
• US7691869B2
  申请人：——

  公开号：US7691869B2

  公开（公告）日：2010-04-06
• US7723343B2
  申请人：——

  公开号：US7723343B2

  公开（公告）日：2010-05-25
• ISMAILOV, V. A.;BAJRAMOV, M. R.;SADYXOV, N. S.;GUSEJNOVA, R. A., AZERB. XIM. ZH.,(1988) N, S. 73-77
  作者：ISMAILOV, V. A.、BAJRAMOV, M. R.、SADYXOV, N. S.、GUSEJNOVA, R. A.

  DOI：——

  日期：——